| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 60 | 2024 | 1172 | 10.600 |
Why?
|
| Cytomegalovirus Infections | 34 | 2024 | 837 | 9.500 |
Why?
|
| Kidney Transplantation | 41 | 2024 | 4277 | 5.560 |
Why?
|
| Cytomegalovirus | 22 | 2024 | 753 | 4.450 |
Why?
|
| Immunocompromised Host | 25 | 2024 | 865 | 3.080 |
Why?
|
| Antiviral Agents | 31 | 2024 | 3068 | 2.980 |
Why?
|
| Tissue Donors | 26 | 2023 | 2389 | 2.130 |
Why?
|
| Medical Tourism | 5 | 2021 | 51 | 2.000 |
Why?
|
| Communicable Diseases | 13 | 2023 | 873 | 1.960 |
Why?
|
| BK Virus | 3 | 2024 | 120 | 1.810 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 5 | 2024 | 37 | 1.740 |
Why?
|
| Polyomavirus Infections | 2 | 2024 | 193 | 1.570 |
Why?
|
| Tumor Virus Infections | 3 | 2024 | 438 | 1.570 |
Why?
|
| Parasitic Diseases | 4 | 2013 | 76 | 1.510 |
Why?
|
| Liver Transplantation | 10 | 2022 | 2417 | 1.390 |
Why?
|
| Respiratory Syncytial Virus Infections | 5 | 2024 | 365 | 1.260 |
Why?
|
| Opportunistic Infections | 6 | 2018 | 376 | 1.220 |
Why?
|
| Vaccines | 6 | 2022 | 840 | 1.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2023 | 5752 | 1.190 |
Why?
|
| Immunosuppressive Agents | 15 | 2024 | 4213 | 1.160 |
Why?
|
| Travel Medicine | 5 | 2019 | 83 | 1.100 |
Why?
|
| Virus Diseases | 5 | 2015 | 720 | 1.050 |
Why?
|
| Acetates | 4 | 2023 | 314 | 1.040 |
Why?
|
| Donor Selection | 6 | 2024 | 242 | 1.030 |
Why?
|
| Dermatomycoses | 3 | 2011 | 45 | 0.990 |
Why?
|
| Kidney Failure, Chronic | 4 | 2022 | 2504 | 0.970 |
Why?
|
| Tissue and Organ Procurement | 8 | 2021 | 988 | 0.930 |
Why?
|
| Pyelonephritis | 1 | 2024 | 77 | 0.920 |
Why?
|
| Lung Transplantation | 5 | 2022 | 1310 | 0.900 |
Why?
|
| Herpesviridae Infections | 2 | 2022 | 268 | 0.820 |
Why?
|
| Vaccination | 13 | 2024 | 3431 | 0.810 |
Why?
|
| Immunity, Cellular | 4 | 2022 | 1557 | 0.810 |
Why?
|
| Travel | 5 | 2024 | 806 | 0.790 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2024 | 239 | 0.790 |
Why?
|
| Blood Donors | 1 | 2024 | 344 | 0.780 |
Why?
|
| Measles | 1 | 2024 | 180 | 0.780 |
Why?
|
| Consensus | 7 | 2024 | 3200 | 0.750 |
Why?
|
| Respiratory Syncytial Virus, Human | 4 | 2024 | 150 | 0.730 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2012 | 453 | 0.710 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 159 | 0.700 |
Why?
|
| Anti-Bacterial Agents | 9 | 2024 | 7474 | 0.670 |
Why?
|
| Anti-Infective Agents | 5 | 2022 | 987 | 0.660 |
Why?
|
| Bacteremia | 2 | 2024 | 987 | 0.650 |
Why?
|
| Ganciclovir | 6 | 2024 | 256 | 0.640 |
Why?
|
| Herpes Simplex | 1 | 2022 | 470 | 0.640 |
Why?
|
| Humans | 163 | 2024 | 766019 | 0.640 |
Why?
|
| Dengue | 1 | 2022 | 258 | 0.630 |
Why?
|
| DNA Virus Infections | 1 | 2018 | 15 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 14 | 2024 | 7423 | 0.620 |
Why?
|
| Torque teno virus | 1 | 2018 | 13 | 0.620 |
Why?
|
| Advisory Committees | 8 | 2024 | 796 | 0.590 |
Why?
|
| Living Donors | 2 | 2021 | 647 | 0.590 |
Why?
|
| Influenza Vaccines | 5 | 2012 | 780 | 0.570 |
Why?
|
| Latent Tuberculosis | 3 | 2021 | 223 | 0.570 |
Why?
|
| Disease Outbreaks | 2 | 2024 | 1761 | 0.570 |
Why?
|
| Graft Rejection | 7 | 2022 | 4504 | 0.560 |
Why?
|
| Disease Transmission, Infectious | 6 | 2017 | 560 | 0.550 |
Why?
|
| Tuberculosis | 3 | 2023 | 2010 | 0.550 |
Why?
|
| Propensity Score | 1 | 2024 | 1973 | 0.530 |
Why?
|
| Cytomegalovirus Vaccines | 2 | 2020 | 20 | 0.510 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2024 | 1882 | 0.490 |
Why?
|
| Monitoring, Immunologic | 2 | 2013 | 99 | 0.490 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 2 | 2024 | 16 | 0.460 |
Why?
|
| Encephalitozoonosis | 1 | 2014 | 2 | 0.460 |
Why?
|
| Encephalitozoon cuniculi | 1 | 2014 | 5 | 0.460 |
Why?
|
| Hepatitis E | 1 | 2015 | 76 | 0.460 |
Why?
|
| Quinazolines | 2 | 2021 | 1366 | 0.460 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2022 | 126 | 0.450 |
Why?
|
| Ribonucleosides | 2 | 2024 | 79 | 0.450 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2013 | 24 | 0.440 |
Why?
|
| Ribavirin | 1 | 2015 | 396 | 0.440 |
Why?
|
| Pandemics | 8 | 2024 | 8724 | 0.420 |
Why?
|
| Drug Resistance, Viral | 8 | 2024 | 868 | 0.410 |
Why?
|
| Jaundice | 1 | 2013 | 94 | 0.410 |
Why?
|
| Epidemics | 1 | 2018 | 515 | 0.400 |
Why?
|
| Aspergillosis | 2 | 2019 | 242 | 0.390 |
Why?
|
| Vancomycin Resistance | 1 | 2012 | 125 | 0.390 |
Why?
|
| Enterococcus faecium | 1 | 2012 | 101 | 0.380 |
Why?
|
| Mycobacterium kansasii | 1 | 2011 | 8 | 0.380 |
Why?
|
| Transplants | 4 | 2022 | 208 | 0.380 |
Why?
|
| Clonorchis sinensis | 1 | 2010 | 3 | 0.370 |
Why?
|
| Alternaria | 1 | 2011 | 41 | 0.360 |
Why?
|
| Liver Abscess | 1 | 2011 | 81 | 0.360 |
Why?
|
| Influenza, Human | 5 | 2017 | 1542 | 0.360 |
Why?
|
| Adenovirus Infections, Human | 1 | 2011 | 76 | 0.350 |
Why?
|
| Trichophyton | 1 | 2010 | 21 | 0.350 |
Why?
|
| Malacoplakia | 2 | 2021 | 15 | 0.350 |
Why?
|
| Meningitis, Bacterial | 1 | 2012 | 222 | 0.350 |
Why?
|
| Pancreas Transplantation | 1 | 2011 | 194 | 0.340 |
Why?
|
| Salmonella Vaccines | 2 | 2006 | 9 | 0.340 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 340 | 0.340 |
Why?
|
| Transplantation | 3 | 2017 | 222 | 0.330 |
Why?
|
| Postoperative Complications | 7 | 2022 | 15804 | 0.320 |
Why?
|
| Antiparasitic Agents | 3 | 2018 | 41 | 0.320 |
Why?
|
| Markov Chains | 1 | 2013 | 970 | 0.320 |
Why?
|
| Aspergillus | 2 | 2015 | 93 | 0.320 |
Why?
|
| Immunization | 5 | 2023 | 1218 | 0.320 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 413 | 0.310 |
Why?
|
| Nephrotic Syndrome | 1 | 2013 | 380 | 0.310 |
Why?
|
| End Stage Liver Disease | 1 | 2013 | 369 | 0.310 |
Why?
|
| Risk Factors | 26 | 2024 | 74837 | 0.310 |
Why?
|
| Cytosine | 2 | 2022 | 212 | 0.310 |
Why?
|
| Hemochromatosis | 1 | 2010 | 175 | 0.310 |
Why?
|
| Cecum | 1 | 2009 | 231 | 0.310 |
Why?
|
| Schistosomiasis mansoni | 1 | 2009 | 94 | 0.310 |
Why?
|
| Steroids | 2 | 2013 | 934 | 0.300 |
Why?
|
| Schistosoma mansoni | 1 | 2009 | 154 | 0.300 |
Why?
|
| Preventive Health Services | 1 | 2013 | 571 | 0.300 |
Why?
|
| Bacterial Infections | 2 | 2014 | 1387 | 0.290 |
Why?
|
| Respiratory Tract Diseases | 2 | 2023 | 744 | 0.290 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2010 | 373 | 0.280 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2008 | 113 | 0.270 |
Why?
|
| Adenoviridae | 1 | 2011 | 1092 | 0.270 |
Why?
|
| Zoonoses | 2 | 2007 | 180 | 0.270 |
Why?
|
| Coccidioides | 1 | 2006 | 17 | 0.260 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 36 | 0.260 |
Why?
|
| Antifungal Agents | 3 | 2019 | 769 | 0.250 |
Why?
|
| Gene Products, gag | 1 | 2006 | 317 | 0.250 |
Why?
|
| Heart Transplantation | 5 | 2021 | 3301 | 0.250 |
Why?
|
| Treatment Outcome | 15 | 2024 | 65203 | 0.250 |
Why?
|
| Hand | 1 | 2011 | 909 | 0.250 |
Why?
|
| Renal Dialysis | 3 | 2024 | 1791 | 0.240 |
Why?
|
| Adult | 40 | 2024 | 223110 | 0.240 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 276 | 0.240 |
Why?
|
| Salmonella Infections | 1 | 2006 | 175 | 0.240 |
Why?
|
| Salmonella typhi | 1 | 2006 | 201 | 0.230 |
Why?
|
| Trypanosoma cruzi | 2 | 2018 | 203 | 0.230 |
Why?
|
| Blood Safety | 1 | 2024 | 16 | 0.230 |
Why?
|
| Registries | 2 | 2018 | 8343 | 0.220 |
Why?
|
| Measles Vaccine | 1 | 2024 | 79 | 0.220 |
Why?
|
| Benzimidazoles | 3 | 2024 | 862 | 0.220 |
Why?
|
| Salmonella typhimurium | 1 | 2006 | 348 | 0.220 |
Why?
|
| Hepatitis B virus | 3 | 2017 | 531 | 0.220 |
Why?
|
| Cephalosporins | 1 | 2024 | 200 | 0.210 |
Why?
|
| Male | 42 | 2024 | 363880 | 0.210 |
Why?
|
| Endemic Diseases | 2 | 2018 | 190 | 0.210 |
Why?
|
| Foscarnet | 1 | 2022 | 36 | 0.210 |
Why?
|
| Chemoprevention | 2 | 2023 | 327 | 0.210 |
Why?
|
| HIV Seropositivity | 1 | 2008 | 961 | 0.200 |
Why?
|
| Immunization Schedule | 3 | 2023 | 229 | 0.200 |
Why?
|
| Middle Aged | 35 | 2024 | 223035 | 0.200 |
Why?
|
| beta-Lactamases | 1 | 2024 | 308 | 0.200 |
Why?
|
| Acyclovir | 1 | 2022 | 266 | 0.190 |
Why?
|
| Administration, Oral | 2 | 2024 | 4016 | 0.190 |
Why?
|
| Hepatitis B | 3 | 2017 | 709 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 1032 | 0.190 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2022 | 49 | 0.190 |
Why?
|
| Rectum | 1 | 2006 | 896 | 0.190 |
Why?
|
| Protozoan Vaccines | 2 | 2012 | 13 | 0.180 |
Why?
|
| Liver | 4 | 2013 | 7558 | 0.180 |
Why?
|
| Anthozoa | 1 | 2021 | 65 | 0.180 |
Why?
|
| Infection Control | 1 | 2008 | 984 | 0.180 |
Why?
|
| Serotonin Syndrome | 1 | 2020 | 18 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2022 | 241 | 0.180 |
Why?
|
| Hemofiltration | 1 | 2021 | 58 | 0.180 |
Why?
|
| Histoplasmosis | 1 | 2020 | 63 | 0.180 |
Why?
|
| Nephrology | 1 | 2024 | 270 | 0.170 |
Why?
|
| Neoplasms | 8 | 2021 | 22336 | 0.170 |
Why?
|
| AIDS Vaccines | 1 | 2006 | 898 | 0.170 |
Why?
|
| Azithromycin | 1 | 2021 | 202 | 0.170 |
Why?
|
| Viremia | 2 | 2023 | 727 | 0.170 |
Why?
|
| Intestines | 2 | 2009 | 1904 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 1961 | 0.160 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 96 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2022 | 641 | 0.160 |
Why?
|
| Vaccines, Attenuated | 3 | 2011 | 314 | 0.160 |
Why?
|
| Feces | 1 | 2006 | 1503 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 8037 | 0.160 |
Why?
|
| Herpes Zoster | 1 | 2022 | 252 | 0.160 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 10260 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 389 | 0.160 |
Why?
|
| Biopsy | 5 | 2013 | 6768 | 0.160 |
Why?
|
| Isoniazid | 1 | 2020 | 279 | 0.160 |
Why?
|
| Death | 2 | 2018 | 685 | 0.160 |
Why?
|
| Pneumonia | 2 | 2024 | 2158 | 0.160 |
Why?
|
| Antigens | 1 | 2004 | 1437 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3801 | 0.160 |
Why?
|
| Bacterial Vaccines | 2 | 2012 | 400 | 0.150 |
Why?
|
| Female | 31 | 2024 | 396174 | 0.150 |
Why?
|
| Mass Screening | 2 | 2021 | 5450 | 0.150 |
Why?
|
| Viral Matrix Proteins | 1 | 2019 | 192 | 0.150 |
Why?
|
| Drug Approval | 2 | 2022 | 820 | 0.150 |
Why?
|
| Simplexvirus | 1 | 2021 | 805 | 0.140 |
Why?
|
| Viral Vaccines | 2 | 2013 | 596 | 0.140 |
Why?
|
| United States | 19 | 2024 | 72918 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 4053 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 804 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2024 | 1307 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 3928 | 0.140 |
Why?
|
| Rhodococcus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 1737 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 4779 | 0.140 |
Why?
|
| Actinomycetales Infections | 1 | 2017 | 30 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 518 | 0.140 |
Why?
|
| Incidence | 5 | 2024 | 21509 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2024 | 1276 | 0.130 |
Why?
|
| Diarrhea | 1 | 2023 | 1315 | 0.130 |
Why?
|
| Polymyxins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Candidemia | 1 | 2017 | 46 | 0.130 |
Why?
|
| Trimethoprim | 1 | 2016 | 79 | 0.130 |
Why?
|
| Immediate-Early Proteins | 1 | 2019 | 444 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1643 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2024 | 54804 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2018 | 166 | 0.130 |
Why?
|
| Triazoles | 2 | 2019 | 902 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2010 | 2431 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 1008 | 0.130 |
Why?
|
| Bacteria | 2 | 2017 | 2211 | 0.120 |
Why?
|
| Immunomodulation | 2 | 2021 | 548 | 0.120 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Risk Assessment | 8 | 2018 | 24272 | 0.120 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2015 | 23 | 0.120 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2015 | 72 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 2056 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 1662 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2015 | 77 | 0.120 |
Why?
|
| West Nile virus | 1 | 2015 | 77 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2024 | 81544 | 0.120 |
Why?
|
| Health Resources | 1 | 2020 | 951 | 0.110 |
Why?
|
| Aged | 19 | 2024 | 171170 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 1794 | 0.110 |
Why?
|
| Tacrolimus | 2 | 2022 | 753 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 2332 | 0.110 |
Why?
|
| Antitubercular Agents | 2 | 2012 | 1380 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 5528 | 0.110 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2014 | 74 | 0.110 |
Why?
|
| Sudan | 1 | 2013 | 86 | 0.110 |
Why?
|
| Immune System | 1 | 2019 | 799 | 0.110 |
Why?
|
| Nitriles | 1 | 2019 | 981 | 0.110 |
Why?
|
| Virginiamycin | 1 | 2012 | 11 | 0.100 |
Why?
|
| Societies, Medical | 5 | 2019 | 3955 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3831 | 0.100 |
Why?
|
| International Agencies | 1 | 2013 | 241 | 0.100 |
Why?
|
| Herpesvirus 6, Human | 1 | 2013 | 96 | 0.100 |
Why?
|
| Hepatitis C | 2 | 2020 | 1596 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6506 | 0.100 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 76 | 0.100 |
Why?
|
| Daptomycin | 1 | 2012 | 71 | 0.100 |
Why?
|
| Oxazolidinones | 1 | 2012 | 99 | 0.100 |
Why?
|
| Cryptosporidiosis | 1 | 2012 | 52 | 0.100 |
Why?
|
| Facial Transplantation | 1 | 2014 | 220 | 0.090 |
Why?
|
| Mycological Typing Techniques | 1 | 2011 | 9 | 0.090 |
Why?
|
| Graft Survival | 3 | 2013 | 3904 | 0.090 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2011 | 27 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2021 | 1971 | 0.090 |
Why?
|
| Clonorchiasis | 1 | 2010 | 5 | 0.090 |
Why?
|
| ROC Curve | 1 | 2019 | 3614 | 0.090 |
Why?
|
| Maxilla | 1 | 2014 | 486 | 0.090 |
Why?
|
| Antibody Formation | 3 | 2023 | 1392 | 0.090 |
Why?
|
| Viral Core Proteins | 1 | 2011 | 158 | 0.090 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 856 | 0.090 |
Why?
|
| Acetamides | 1 | 2012 | 260 | 0.090 |
Why?
|
| Enteritis | 1 | 2012 | 162 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2016 | 497 | 0.090 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 95 | 0.090 |
Why?
|
| Length of Stay | 1 | 2024 | 6489 | 0.090 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 148 | 0.090 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 131 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 667 | 0.080 |
Why?
|
| DNA, Fungal | 1 | 2011 | 275 | 0.080 |
Why?
|
| Caregivers | 1 | 2022 | 2304 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2009 | 1836 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 1404 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2023 | 3159 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 733 | 0.080 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 620 | 0.080 |
Why?
|
| Listeria monocytogenes | 1 | 2011 | 245 | 0.080 |
Why?
|
| Fungal Vaccines | 1 | 2008 | 7 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2565 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2010 | 695 | 0.080 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2010 | 217 | 0.080 |
Why?
|
| HIV-1 | 1 | 2006 | 6948 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2011 | 3399 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1943 | 0.080 |
Why?
|
| Debridement | 1 | 2011 | 494 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 10577 | 0.070 |
Why?
|
| Cross Infection | 1 | 2017 | 1427 | 0.070 |
Why?
|
| Hepacivirus | 3 | 2020 | 1343 | 0.070 |
Why?
|
| Tachycardia, Sinus | 1 | 1997 | 43 | 0.070 |
Why?
|
| Immunity, Mucosal | 1 | 2011 | 498 | 0.070 |
Why?
|
| Young Adult | 7 | 2021 | 59858 | 0.070 |
Why?
|
| Transplantation Immunology | 2 | 2010 | 540 | 0.070 |
Why?
|
| Amlodipine | 1 | 1997 | 84 | 0.070 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2021 | 335 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 810 | 0.070 |
Why?
|
| Nucleic Acids | 1 | 2010 | 189 | 0.070 |
Why?
|
| Disease Vectors | 1 | 2007 | 61 | 0.070 |
Why?
|
| Peptides | 1 | 2019 | 4338 | 0.070 |
Why?
|
| Pyridines | 1 | 2019 | 2889 | 0.070 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 3212 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2017 | 2778 | 0.070 |
Why?
|
| Heart | 1 | 2019 | 4416 | 0.060 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 245 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 790 | 0.060 |
Why?
|
| U937 Cells | 1 | 2006 | 259 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 355 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2009 | 12975 | 0.060 |
Why?
|
| Serologic Tests | 2 | 2018 | 382 | 0.060 |
Why?
|
| Fibrosis | 1 | 2013 | 2073 | 0.060 |
Why?
|
| Brain Death | 1 | 2009 | 360 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2015 | 1552 | 0.060 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 140 | 0.060 |
Why?
|
| Animals | 10 | 2021 | 168801 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2008 | 308 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1592 | 0.060 |
Why?
|
| Coma | 1 | 2009 | 485 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 1283 | 0.060 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 176 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9237 | 0.060 |
Why?
|
| North America | 2 | 2022 | 1287 | 0.060 |
Why?
|
| Child | 8 | 2017 | 80567 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 409 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2013 | 2249 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 686 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2021 | 961 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 1362 | 0.050 |
Why?
|
| International Cooperation | 1 | 2010 | 1433 | 0.050 |
Why?
|
| Babesia microti | 1 | 2003 | 31 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2022 | 1673 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1434 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2005 | 253 | 0.050 |
Why?
|
| New England | 1 | 2006 | 1059 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 2 | 2023 | 2011 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 550 | 0.050 |
Why?
|
| Babesiosis | 1 | 2003 | 92 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15403 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1883 | 0.050 |
Why?
|
| Borrelia burgdorferi | 1 | 2003 | 183 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2024 | 433 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 1992 | 212 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2006 | 704 | 0.050 |
Why?
|
| Flucytosine | 1 | 2021 | 31 | 0.050 |
Why?
|
| Hypotension | 1 | 1997 | 885 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 1331 | 0.050 |
Why?
|
| Histoplasma | 1 | 2020 | 40 | 0.040 |
Why?
|
| Causality | 1 | 2007 | 1247 | 0.040 |
Why?
|
| Infant | 4 | 2023 | 36424 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 2411 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 349 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2022 | 777 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2013 | 5988 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1992 | 2921 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2007 | 1186 | 0.040 |
Why?
|
| Multigene Family | 1 | 1992 | 1081 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2009 | 1516 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 6308 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2006 | 13400 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2022 | 4860 | 0.040 |
Why?
|
| Capsules | 1 | 2019 | 192 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 8494 | 0.040 |
Why?
|
| Prognosis | 2 | 2011 | 29905 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14644 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3689 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2022 | 681 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 17597 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 497 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 892 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2018 | 5946 | 0.040 |
Why?
|
| Prevalence | 1 | 2015 | 15820 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3733 | 0.040 |
Why?
|
| Developing Countries | 2 | 2013 | 2913 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 337 | 0.040 |
Why?
|
| Lyme Disease | 1 | 2003 | 627 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 296 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6215 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2021 | 9655 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 832 | 0.030 |
Why?
|
| Patient Selection | 1 | 2009 | 4249 | 0.030 |
Why?
|
| Time Factors | 3 | 2018 | 40100 | 0.030 |
Why?
|
| Brain | 2 | 2019 | 27175 | 0.030 |
Why?
|
| Jejunum | 1 | 2019 | 474 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 789 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2018 | 492 | 0.030 |
Why?
|
| Latin America | 1 | 2018 | 416 | 0.030 |
Why?
|
| Skin | 1 | 2010 | 4482 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4282 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 791 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2017 | 42509 | 0.030 |
Why?
|
| Nifurtimox | 1 | 2015 | 14 | 0.030 |
Why?
|
| Carbapenems | 1 | 2017 | 125 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2018 | 303 | 0.030 |
Why?
|
| Trypanocidal Agents | 1 | 2015 | 40 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2013 | 6057 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 614 | 0.030 |
Why?
|
| Aspergillus flavus | 1 | 2015 | 13 | 0.030 |
Why?
|
| Scedosporium | 1 | 2015 | 10 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 956 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2015 | 90 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2013 | 2200 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 2015 | 226 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 118 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 779 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2015 | 156 | 0.030 |
Why?
|
| Acute Disease | 1 | 2005 | 7237 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3240 | 0.030 |
Why?
|
| Curriculum | 2 | 2018 | 3784 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 702 | 0.030 |
Why?
|
| India | 1 | 2020 | 2334 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 641 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 368 | 0.030 |
Why?
|
| Oropharynx | 1 | 2014 | 139 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2010 | 7850 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 2076 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2120 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 2653 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 802 | 0.030 |
Why?
|
| Viral Load | 1 | 2021 | 3386 | 0.020 |
Why?
|
| Adolescent | 4 | 2021 | 88808 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2019 | 1536 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2021 | 41677 | 0.020 |
Why?
|
| DNA | 2 | 2024 | 7192 | 0.020 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 267 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1600 | 0.020 |
Why?
|
| Nucleocapsid Proteins | 1 | 2011 | 75 | 0.020 |
Why?
|
| European Union | 1 | 2012 | 157 | 0.020 |
Why?
|
| Geography | 1 | 2013 | 651 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2011 | 113 | 0.020 |
Why?
|
| HIV | 1 | 2017 | 1587 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20699 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1980 | 0.020 |
Why?
|
| Genotype | 1 | 2024 | 13027 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 2232 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 1134 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 1065 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2009 | 186 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2021 | 4209 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2019 | 4188 | 0.020 |
Why?
|
| HIV Infections | 3 | 2017 | 17535 | 0.020 |
Why?
|
| Fever | 2 | 2008 | 1607 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1990 | 711 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3382 | 0.020 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1990 | 249 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 894 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 2838 | 0.020 |
Why?
|
| Internationality | 1 | 2013 | 1006 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3798 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2008 | 191 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 791 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2008 | 102 | 0.020 |
Why?
|
| Lung | 2 | 2021 | 10061 | 0.020 |
Why?
|
| Neurology | 1 | 2014 | 784 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3428 | 0.020 |
Why?
|
| Arenaviridae Infections | 1 | 2006 | 53 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 445 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 353 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 922 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 354 | 0.020 |
Why?
|
| Virus Replication | 1 | 2013 | 2458 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2005 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1990 | 908 | 0.010 |
Why?
|
| Social Class | 1 | 2013 | 2006 | 0.010 |
Why?
|
| Mutation | 2 | 2024 | 30210 | 0.010 |
Why?
|
| Erythrocyte Inclusions | 1 | 2003 | 4 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 500 | 0.010 |
Why?
|
| Radiography | 1 | 2015 | 6943 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 81838 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1990 | 2945 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2234 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 2543 | 0.010 |
Why?
|
| Sweating | 1 | 2003 | 155 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2413 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 164 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1992 | 4163 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 363 | 0.010 |
Why?
|
| Pharyngitis | 1 | 2003 | 221 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1992 | 556 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2017 | 4859 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 30228 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2008 | 1069 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18382 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1056 | 0.010 |
Why?
|
| Hospitalization | 1 | 2021 | 10804 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 1910 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 744 | 0.010 |
Why?
|
| Sarcoma | 1 | 1990 | 1801 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 4555 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2017 | 22230 | 0.010 |
Why?
|
| Critical Care | 1 | 2011 | 2714 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1997 | 1412 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36547 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39233 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8882 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 1739 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1992 | 3070 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 59497 | 0.010 |
Why?
|
| Dyspnea | 1 | 2003 | 1351 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3743 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 14065 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2003 | 2394 | 0.010 |
Why?
|
| Cell Line | 2 | 1992 | 15545 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1992 | 2677 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 7072 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 167 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 848 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1990 | 765 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 26280 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1990 | 417 | 0.010 |
Why?
|
| Codon | 1 | 1990 | 599 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 780 | 0.000 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1990 | 1677 | 0.000 |
Why?
|
| Germ Cells | 1 | 1990 | 646 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 2469 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1990 | 21072 | 0.000 |
Why?
|
| Pedigree | 1 | 1990 | 4535 | 0.000 |
Why?
|
| Transfection | 1 | 1990 | 5739 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1990 | 5879 | 0.000 |
Why?
|
| Base Sequence | 1 | 1990 | 12405 | 0.000 |
Why?
|
| Genetic Testing | 1 | 1990 | 3592 | 0.000 |
Why?
|